Research shows the inhibitor of HSP90, 17-Allylamino-17-deoxykygdanamycin (17-AAG), inhibits the growth of glioma cell lines by targeting intracellular EGFR, AKT, and MAPK proteins 22. Here, EGFR is linked to central nervous system cancer.